問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Kaoshiung Chang Gung Memorial Hospital of the C.G.M.F.

List

1364Cases

2013-11-29 - 2013-11-29

Phase II

A Double-blind, Randomized, Vehicle-controlled, Parallel-group, Phase II Dose-ranging Study to Evaluate the Efficacy and Safety of SR-T100 Gel in Common Warts (CW) Patients.

  • Condition/Disease

    Common Warts / Verruca Vulgaris (CWs)

  • Test Drug

    SR-T100

Participate Sites
4Sites

Study ended4Sites

2009-06-01 - 2012-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated1Sites

Study ended4Sites

2010-04-01 - 2013-04-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2009-07-01 - 2011-06-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Terminated10Sites

2010-12-01 - 2017-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Study ended9Sites

2011-04-01 - 2019-03-19

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2011-04-01 - 2015-10-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Study ended6Sites

2010-05-01 - 2014-07-31

Phase III

Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid β Antibody in Patients with Alzheimer’s Disease.

  • Condition/Disease

    Alzheimer's disease

  • Test Drug

    Solanezumab

Participate Sites
6Sites

Terminated6Sites

2010-12-01 - 2014-01-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Terminated12Sites

2011-04-01 - 2014-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Terminated11Sites

1 114 115 116 117 118 137
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB